Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Baiyunshan: Acquisition of 100% Equity of Zhejiang Pharmaceutical Industry Co., Ltd.
Recently, Baiyunshan announced that on December 17, 2025, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (“the Company”)'s subsidiary, Guangzhou Pharmaceutical Co., Ltd. (“Guangzhou Pharma”), signed the “Equity Transaction Contract of Zhejiang Medical Industry Co., Ltd.” (“Equity Transaction Contract”) with Zhejiang Hisun Pharmaceutical Co., Ltd. (“Hisun Pharma”), along with the “Supplementary Agreement to the Equity Transaction Contract of Zhejiang Medical Industry Co., Ltd.” Guangzhou Pharma acquired 100% equity of Zhejiang Medical Industry Co., Ltd. (“Zhejiang Medical” or “Target Company”) held by Hisun Pharma through a public tender, with a transfer price of RMB 500.50 million.
As of now, Guangzhou Pharma has paid the full equity transfer amount to Hisun Pharma in accordance with the Equity Transaction Contract. Zhejiang Medical has completed the necessary business registration changes, and the equity transfer and registration of the Target Company have been finalized. Guangzhou Pharma now owns 100% of Zhejiang Medical, which has been included in Guangzhou Pharma’s consolidated financial statements. The entire equity transaction has been completed.
(Baiyunshan Announcement)
(Edited by: Yang Yan, Lin Chen)
Keywords: Healthcare